Sutent misses OS endpoint in NSCLC study

Pfizer Inc. (NYSE:PFE) said top-line data showed Sutent sunitinib plus Tarceva erlotinib missed the primary endpoint of significantly improving overall survival (OS) vs. placebo plus Tarceva in the Ph...